Palivizumab: profile and news

MedImmune Awarded $170 Million Five-Year Contract From US Health ... May 10, 2006
...commented: "For the last 10 years, we have used our extensive experience with cell-based technology to manufacture Synagis(R) (palivizumab), a monoclonal ... - Webbolt Business News,

MedImmune Reports Financial Results for First Quarter 2006 Apr 20, 2006
..."As described on our year-end earnings call in February, several factors impacted US sales of Synagis® (palivizumab) at the outset of the 2005-2006 ... - Yahoo! News (press release)

Other information

Indication
For treatment of respiratory diseases casued by respiratory syncytial virus

Pharmacology
Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.

Mechanism Of Action
Binds to the outer coat or Fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.

Drug Category
Antiviral Agents; monoclonal antibodies (08:18.24)

Brand Names/Synonyms
Synagis; anti-RSV; Synagis (MedImmune Inc)

Dosage Forms
POWDER FOR SOLUTION

Absorption
Not Available

Interactions
Not Available

Chemical IUPAC Name
Humanized anti-RSV antibody

Chemical Formula
Not Available

Half Life
18 days (in adults)

Drug Type
Approved Drug

# Accession No
BIOD00097

CAS Registry Number
60574-4111-01